Return to Today's science sparks archives
Click the tweet icon above each article title to share it on Twitter.
|
Figure 4. This flowchart shows the generalized overview of the neoadjuvant and adjuvant studies from patient image acquisition (CT, MRI, PET), tumor segmentation, radiomic signature, machine learning analysis, and the predicted outcome in the traditional machine learning radiomics approach versus the deep learning approach.
|
 |
|
Fig. 1. Circos plots showing NTRK gene fusions by frequency and tumor type (A–C) and by chromosomal localization (D–F).
|
|
|
Fig. 2: Copper depletion targets SOX2/OCT4+ metastatic cells.
|
|
|
Fig. 1: Matched ADRN and MES cell lines show prominent differences in telomere protein expression and localization.
|
|
|
Figure 1. Differentially Expressed MicroRNAs (miRNAs) in Stage I vs Stage II or III Rectal Cancers in the American College of Surgeons Oncology Group/Timing of Rectal Cancer Response to Chemoradiation Cohort.
|
|
|
Figure 1. Example of a gift created by a participant for a relationship depicted in a painting viewed during Family session 2.
|
|
|
Fig. 2. Adjusted odds ratios for preoperative satisfaction.
|
|
|
Fig. 1 Longitudinal changes in objective cognitive scores of processing speed (Trail Making A), executive functioning (Trail Making B), and working memory (Digit Span).
|
|
|
Figure 1. Waterfall plot showing the distribution of the best percentage changes in the sum of the target lesion size from the baseline for individual patients.
|
|
|
Fig 2. Targeted 1-mm biopsy enables diagnosis, feature and depth correlation, and molecular pathology.
|
|
|
Fig 1. Molecular profile of MSI-H colorectal cancer patients.
|
|
|
Figure 1 Race of eligible patients for immunotherapies and tumor mutation burden (TMB) cutoffs.
|
|
|
Fig 1. Distribution of texture risk score for unilateral breast cancer (UBC) controls and contralateral breast cancer (CBC) cases in the WECARE Study.
|
|
|
Fig 1. Perception-based nanosensor platform for protein biomarkers.
|
|
|
Fig 1. SARS-CoV-2 replicon design and launch optimization.
|
|
|
Fig 1. Overlap of CAR-T–Reported CPAEs.
|
|
|
Fig. 1. Current management algorithm on detection of a presumed meningioma integrating genomic features.
|
|
|
Figure 1: Defining acquired resistance to immunotherapy.
|
|
|
Fig. 2: MAPK activating mutations promote resistance to HER2 inhibition.
|
|
|
Figure 1 Wilms tumor chemical screens.
|
|
|
Fig. 1 Process of genetic counseling and testing.
|
|
|
Fig 1. The chromosomal basis of gene fusions.
|
|
|
Fig. 2. L-Arginine improves the effect of radiation therapy in patients with BM.
|
|
|
Fig 3. Spectrum of somatic alterations associated with response to immune-checkpoint blockade (ICB)
|
|
|
Fig 1. A) Trainee reported experience (in numbers of cases) with the treatment of individual hematologic malignancies diagnoses and specialized radiation therapy techniques. B) Trainee reported comfort with various aspects of hematologic malignancies patient care
|
|
|
Fig. 5: Dispensability of germline pathogenicity in tumorigenesis.
|
|
|
Visual Abstract.
|
|
|
Graphical Abstract.
|
|
|
Fig. 3: The tumor–microenvironment interface is composed of specialized tumor and muscle cells.
|
|
|
Fig. 6. Sankey diagram shows management decisions before (left) and after (right) 18F-FDG-PET and PET/CT in patients with cancer of unknown primary.
|
|
|
Graphical Abstract
|
|
|
Figure 2. Timeline of Important Dates.
|
|
|
Figure 3. Patient assessment of the telemedicine on-treatment management visit.
|
|
|
Fig. 3: Mitochondrial GSH import is essential for cell proliferation.
|
|
|
Abstract.
|
|
|
Figure 3 Overall survival and progression-free survival in resected patients (A) and unresected patients (B).
|
|
|
Graphical Abstract
|
|
|
Fig. 1: Genomic landscape of RAD51B-associated cancers.
|
|
|
Figure 3. TAM and T cell phenotypes associated with response to optimized therapy regimen.
|
|
|
Fig 1. Model of metabolic regulation of tumor immunogenicity: oncogenic-driven metabolic rewiring required for cancer cell growth can promote tumor immunogenicity.
|
|
|
Fig. 1: Immune cell atlas of the LR-CHL microenvironment at single-cell resolution.
|
|
|
Fig. 1. Maximal response to therapy by mutation status in patients with NSCLC.
|
|
|
Fig. 2. Magnetic resonance imaging (MRI) of histiocytoses of the nervous system.
|
|
|
Fig. 3. Absolute contralateral breast cancer risk by PRS percentiles per age category of the first breast cancer diagnosis for BRCA1 and BRCA2 heterozygotes.
|
|
|
Figure 1. Four domains of research according to Patient-Centered Outcomes Research Institute.
|
|
|
Visual Abstract.
|
|
|
Figure 1. WBC count vs time (in months) with major events labeled.
|
|
|
Fig. 2: Building an integrative oncogene-dependency map of EGFRT790M/L858R, KRASG12V, and RIT1M90I
|
|
|
Figure 2. Exon-exon junctions reads.
|
|
|
Figure 3. OncoPrint plots of risk scores with mutational burden, sex, smoking status, asbestos exposure, histology, and mutation status for the top mutated genes.
|
|
|
Fig 1. 124I activity concentration in the phantom’s spheres as a function of increasing 131I activity in the background measured on the PET image reconstructed with the OSEM algorithm with 2 iterations and 16 subsets, TOF information and PSF modeling.
|
|
|
Fig 2. Immunotype classification significantly correlates with survival in ICB-treated patients with melanoma.
|
|
|
Figure 1. Intestinal homeostasis is tightly controlled by gut microbiota through a large number of microbial metabolites/components.
|
|
|
Graphical abstract.
|
|
|
Figure. Overview of Data Sets and Studies.
|
|
|
Figure 2. Long-term United States and worldwide interest in search terms related to the diagnostic and therapeutic options of interventional radiology.
|
|
|
Fig 1 Adjusted overall survival for five years after landmark time points for first autologous haematopoietic cell transplantation in mantle cell lymphoma.
|
|
|
Figure 4: Sankey diagrams of patients with (A) prostate, (B) colorectal, (C) breast, (D) lung, (E) kidney and bladder, and (F) pancreatic primary cancers and their most common first and second sites of metastasis to nodal (in green) and nonnodal (bone: purple; liver: red; lung: blue; peritoneum: yellow; pleura: orange) organs.
|
|
|
Figure 5. Residues that interact with E2˜SUMO are mostly conserved between Siz2 and Siz1.
|
|
|
Fig 1. Bladder cancer can be classified into various molecular subtypes based on gene expression profiling.
|
|
|
Fig 1. The NXF1 mRNA export pathway. The major pathway for mRNA export from the nucleus to the cytoplasm in metazoans is regulated by a heterodimeric receptor composed of the proteins NXF1 bound to NXT1.
|
|
|
Fig. 1. Predicted probability of any moderate or greater toxicity over time during and after treatment based on treatment type.
|
|
|
Fig 1. Profiling single T cells in NSCLC treated with neoadjuvant PD-1 blockade.
|
|
